PURPOSE: A dividable galenical form which is able to control the release of effective ingredient is provided to partially overcome problem related to re-dividing of tablet. CONSTITUTION: A dividable control-release tablet comprises effective ingredient, cellulose derivative and binder. The effective ingredient is gliclazide. The cellulose derivative is hydroxy methyl cellulose, a hydroxyethylcellulose, hydroxypropylmethylcellulose and/or hydroxypropyl cellulose.

The present invention relates to an extended release (XL) pharmaceutical tablet composition for oral administration and methods of its manufacture. More particularly, the present invention relates to an extended release gliclazide formulation which does not increase the blood glucose level in human patients.

Herein are described pharmaceutical formulations comprising gliclazide as the active ingredient, in combination with hydrophilic ingredients, a hydroxypropyl methylcellulose and lipophilic ingredients having a low melting point in the form of dust-free granules, which without further manipulation result suitable for the preparation of tablets.

The present invention relates to an extended release (XL) pharmaceutical tablet composition for oral administration and methods of its manufacture. More particularly, the present invention relates to an extended release gliclazide formulation which does not increase the blood glucose level in human patients.

The present invention relates to prolonged release tablets. Tablets which are the subject of invention have not content excipients which have a high glisemic index and show uniformity release profile in pH 6.4 -7.2.

A sustained release dosage form comprising a sulfonylurea compound preferably gliclazide or pharmaceutically acceptable salt thereof as active ingredient. The dosage form comprises water-swellable polymer a pH modifier selected from sodium hydrogen carbonate potassium hydrogen carbonate sodium carbonate potassium carbonate magnesium carbonate and calcium carbonate a diluent modifier selected from mannitol and microcrystallised cellulose and preferably as well a sparingly soluble or non-soluble d...

The present invention is directed to stabilized controlled release dosage form of Gliclazide exhibiting pH independent release profile over a wide range having one or more release controlling polymer and free from saccharide component and optionally free from binder and process for preparing such dosage form.